Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a 12 weeks study aimed at assessing the safety and efficacy of 2 doses of AB1010 in
patients suffering from indolent systemic mastocytosis with handicap.